Facebook Twitter LinkedIn Google Plus RSS

Cancer Genetics closes IPO

By ,

Rutherford-based Cancer Genetics Inc., a diagnostics company focused on developing genomic-based oncology tests and services, today announced it has closed its initial public offering of 690,000 shares of common stock at a price to the public of $10 per share.

Total gross proceeds from the offering were $6.9 million before deducting underwriting discounts and commissions and other offering expenses payable by Cancer Genetics, according to the company.

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy


Subscribe to Our Newsletters!
Click Here to Subscribe for Free Now!